Hong Kong
· Delayed Price · Currency is HKD CARsgen Therapeutics Holdings Company Description
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States.
The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL).
It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma.
In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in Phase I clinical trial for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia that is in pre-clinical stage.
Further, it develops AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer.
The company has a license agreement with HK Inno.N Corporation to develop and commercialize CT032 for the treatment of CD19.
The company was founded in 2014 and is headquartered in Shanghai, China.
| Country | Cayman Islands |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 465 |
| CEO | Zonghai Li |
Contact Details
Address: No. 466 Yindu Road Shanghai China | |
| Phone | 86 21 6450 1828 |
| Website | carsgen.com |
Stock Details
| Ticker Symbol | 2171 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG1996C1006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Zonghai Li M.D., Ph.D. | Co-Founder, Chief Executive Officer, Chief Scientific Officer and Chairman of the Board |
| Dr. Huamao Wang Ph.D. | Co-Founder, Chief Operating Officer and Executive Director |
| Dr. Hua Jiang | Executive Director |
| Wing Yat Lui | Company Secretary |